A DOUBLE-BLIND, RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDY TO COMPARE EFFICACY AND SAFETY OF CT-P16 AND EU-APPROVED AVASTIN AS FIRST-LINE TREATMENT FOR METASTATIC OR RECURRENT NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
- Conditions
- -C34 Malignant neoplasm of bronchus and lungMalignant neoplasm of bronchus and lungC34
- Registration Number
- PER-043-18
- Lead Sponsor
- CELLTRION, INC.,
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 20
Each patient must meet all of the following criteria to be randomized in this study:
1.Patient (male or female) between 18 and 75 years of age (both inclusive).
2.Patient must have confirmed non-squamous non-small cell lung cancer (nsNSCLC) by hematoxylin and eosin staining and immunohistochemistry.
3.Patient must be diagnosed as recurrent disease or stage IV according to the American Joint Committee on Cancer (AJCC) Lung Cancer Staging 8th edition. Stage IV is defined as below:
•Separate tumor nodule(s) in a contralateral lobe, or
•Tumor with pleural or pericardial nodules, or
•Malignant pleural or pericardial effusion related to tumor, or
•Single or multiple extrathoracic metastases in a single organ or in multiple organs
4.Patient must have at least 1 measurable lesion by Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1. Target lesions situated in a previously irradiated area are considered measurable if recurrence has been demonstrated in such lesions.
c.Tumor lesions: ≥ 10 mm in long axis by computerized tomography (CT) scan, or
d.Malignant lymph nodes: ≥ 15 mm in short axis by CT scan
5.Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (Oken et al., 1982).
6.Life expectancy > 6 months based on clinical judgement.
7.Negative result in both epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearrangement which is confirmed by biopsy or cytology specimens.
8.Patient must have adequate organ function as follows. These tests must be performed within 14 days prior to Day 1 of Cycle 1.
Bone marrow reserve:
d.Hemoglobin ≥ 9.0 g/dL, and
e.Absolute neutrophil count ≥ 1,500/mm3, and
f.Platelet count ≥ 100,000/mm3
Hepatic:
c.Alkaline phosphatase, aspartate aminotransferase and alanine aminotransferase ≤ 2.5 × upper limit of normal (ULN) (≤ 5.0 × ULN with liver metastasis), and
d.Total bilirubin ≤ 1.5 × ULN
Renal:
d.Serum creatinine ≤ 1.5 × ULN, and
e.Creatinine clearance (CrCl) rate ≥ 45 mL/min, and
f.Urine dipstick for proteinuria < 1+ (i.e., either 0 or trace); if urine dipstick is ≥ 1+ then < 1.0 g of protein in 24 hours urine collection must be confirmed to allow participation in the study
9.Patient and their partner of childbearing potential must agree to use acceptable birth control methods throughout the study and for 6 months after the last dose of assigned treatment (see Section 6.5.2.8).
A man or woman is of childbearing potential if, in the opinion of the investigator, he or she is biologically capable of having children and is sexually active. Male and female patients and their partners who have been surgically sterilized for less than 24 weeks prior to the date of informed consent must agree to use any medically acceptable methods of contraception. Menopausal females must have experienced their last period more than 1 year prior to the date of informed consent to be classified as not of childbearing potential.
10.Patient has the ability to comprehend the full nature and purpose of the study, including possible risks and side effects, to cooperate with the investigator, to understand verbal and/or written instructions, and to comply with the requirements of the entire study.
11.Patient and/or their legally authorized repr
Patients meeting any of the following criteria will be excluded from the study:
1.Patient who has predominantly squamous cell histology non-small cell lung cancer (NSCLC). Mixed tumors will be categorized by the predominant cell type; if small cell elements are present, the patient is ineligible.
2.Patient who has clinically significant third-space fluid; for example, ascites or pleural effusions that cannot be controlled by drainage or other procedures prior to Day 1 of Cycle 1.
3.Patient who has known central nervous system metastases.
4.Patient who has a tumor which has invaded major blood vessels or presence of a cavitated tumor. However, a cavitation with small size (< 1 cm) at peripheral location can be allowed based on investigator’s discretion.
5.Patient who has received previous anti-cancer systemic therapy including one or more of the following(s):
a.Cytotoxic chemotherapy for metastatic nsNSCLC,
b.Cytotoxic chemotherapy for non-metastatic nsNSCLC within 12 months prior to Day 1 of Cycle 1,
c.Anti-neoplastic biological therapy, immunotherapy or targeted therapy,
d.Bevacizumab (or a bevacizumab proposed biosimilar product).
6.Patient who has received previous surgical procedure including one or more of the following(s):
a.Surgery for metastatic nsNSCLC,
b.Surgery for non-metastatic nsNSCLC within 6 months prior to Day 1 of Cycle 1,
c.Open biopsy or open pleurodesis within 28 days prior to Day 1 of Cycle 1,
d.Core biopsy or other minor surgical procedure (e.g. placement of vascular access device, closed pleurodesis, thoracentesis, and mediastinoscopy) within 14 days prior to Day 1 of Cycle 1.
7.Patient who has received previous anti-cancer radiotherapy including one or more of the following(s):
a.Radiotherapy for metastatic nsNSCLC, but radiotherapy as part of the palliative therapy at least 21 days prior to Day 1 of Cycle 1 is allowed,
b.Radiotherapy for non-metastatic nsNSCLC within 6 months prior to Day 1 of Cycle 1,
c.Any toxicity related with radiotherapy prior to Day 1 of Cycle 1.
8.Patient who has a medical history of disease including one or more of the following(s):
n.Clinically significant allergic reactions such as asthma, urticaria, angio-oedema, and eczematous dermatitis, hypersensitivity to any component of carboplatin, paclitaxel, bevacizumab and Chinese Hamster Ovary (CHO) cell products or other recombinant human or humanized antibodies.
o.Cardiac, gastrointestinal, renal, hepatic, hematological (including pancytopenia, aplastic anemia or blood dyscrasia), metabolic (including known diabetes mellitus), autoimmune disease, or pulmonary diseases classed as significant in the opinion of the investigator.
p.A known infection with hepatitis B (active or carrier of hepatitis B), hepatitis C, or infection with human immunodeficiency virus (HIV). However, a patient with past hepatitis B virus is allowed if resolved.
q.Any grade of heart failure, severe uncontrolled cardiac disease (unstable angina, clinically significant electrocardiogram [ECG] abnormalities, etc.), or myocardial infarction, within 6 months prior to Day 1 of Cycle 1.
r.Malignancy or history of malignancy other than NSCLC in the past 5 years except adequately treated squamous or basal cell carcinoma of the skin or carcinoma in situ of the cervix.
s.Any recent infection requiring a course of systemic an
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method